We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
-19.25%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$585M
AUM Growth
-$382M
(-40%)
Cap. Flow
-$229M
Cap. Flow
% of AUM
-39.19%
Top 10 Holdings %
Top 10 Hldgs %
61.33%
Holding
429
New
88
Increased
84
Reduced
102
Closed
122
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Energy Transfer Partners
ET
|
+$50.2M |
| 2 |
Enterprise Products Partners
EPD
|
+$8.56M |
| 3 |
Oneok
OKE
|
+$8.36M |
| 4 |
AM
ANTERO MIDSTREAM PARTNERS LP
AM
|
+$3.06M |
| 5 |
PSXP
PHILLIPS 66 PARTNERS LP
PSXP
|
+$2.72M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ETP
Energy Transfer Partners, L.P.
ETP
|
+$77.3M |
| 2 |
Marathon Petroleum
MPC
|
+$28.8M |
| 3 |
EEP
Enbridge Energy Partners
EEP
|
+$23.6M |
| 4 |
Phillips 66
PSX
|
+$16.9M |
| 5 |
Williams Companies
WMB
|
+$16.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 82.73% |
| 2 | Healthcare | 7.29% |
| 3 | Utilities | 2.06% |
| 4 | Financials | 0.12% |
| 5 | Technology | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
UBX
101
DELISTED
Unity Biotechnology
UBX
| $309K | 0.05% |
+1,899
| New | +$252K |
|
|
MRTX
102
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $309K | 0.05% |
7,284
-2,291
| -24% | -$91.3K |
|
103
CytomX Therapeutics
CTMX
$705M
| $308K | 0.05% |
20,415
+1,565
| +8% | +$23.2K |
|
104
Kura Oncology
KURA
$922M
| $308K | 0.05% |
21,970
-3,468
| -14% | -$45.9K |
|
105
uniQure
QURE
$2.68B
| $308K | 0.05% |
10,678
-2,773
| -21% | -$77.2K |
|
|
BHVN
106
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $308K | 0.05% |
8,320
-3,305
| -28% | -$119K |
|
107
Denali Therapeutics
DNLI
$3.67B
| $306K | 0.05% |
14,790
-10,928
| -42% | -$198K |
|
108
Savara
SVRA
$1.13B
| $305K | 0.05% |
+40,308
| New | +$363K |
|
109
Madrigal Pharmaceuticals
MDGL
$12.6B
| $304K | 0.05% |
2,700
+1,122
| +71% | +$174K |
|
110
Ascendis Pharma A/S
ASND
$16.7B
| $300K | 0.05% |
+4,789
| New | +$301K |
|
|
SGMO
111
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $300K | 0.05% |
26,120
-4,015
| -13% | -$49.9K |
|
112
Xencor
XNCR
$1.44B
| $298K | 0.05% |
8,229
-3,280
| -28% | -$120K |
|
113
PTC Therapeutics
PTCT
$6.37B
| $297K | 0.05% |
8,648
-3,678
| -30% | -$132K |
|
|
SRNE
114
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $297K | 0.05% |
123,823
+61,132
| +98% | +$200K |
|
115
Neuronetics
STIM
$120M
| $296K | 0.05% |
+15,272
| New | +$335K |
|
116
Franklin FTSE India ETF
FLIN
$2.69B
| $295K | 0.05% |
13,338
-12,425
| -48% | -$260K |
|
|
FPRX
117
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $292K | 0.05% |
31,427
+4,603
| +17% | +$54.8K |
|
|
BLUE
118
DELISTED
bluebird bio
BLUE
| $291K | 0.05% |
227
+41
| +22% | +$62.9K |
|
119
Rocket Pharmaceuticals
RCKT
$348M
| $291K | 0.05% |
19,604
-2,170
| -10% | -$36K |
|
|
GBT
120
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $291K | 0.05% |
7,094
-2,959
| -29% | -$111K |
|
|
XLRN
121
DELISTED
Acceleron Pharma
XLRN
| $291K | 0.05% |
6,685
-6,419
| -49% | -$321K |
|
|
AKCA
122
DELISTED
Akcea Therapeutics Inc
AKCA
| $290K | 0.05% |
9,610
-9,819
| -51% | -$275K |
|
|
BPMC
123
DELISTED
Blueprint Medicines
BPMC
| $289K | 0.05% |
5,364
-956
| -15% | -$58.1K |
|
|
ESPR
124
DELISTED
Esperion Therapeutics
ESPR
| $289K | 0.05% |
6,279
-5,018
| -44% | -$242K |
|
125
Exelon
EXC
$48.6B
| $289K | 0.05% |
8,973
| – | – |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q4 2018 Portfolio in Review
As of Q4 2018, Virtus ETF Advisers held 429 positions worth $585M, down 40% from $968M the previous quarter. Its ten largest holdings account for 61% of the portfolio.
Virtus ETF Advisers withdrew a net $229M in Q4 2018, closing 122 positions and reducing 102 holdings. Its most notable exit was Energy Transfer Partners, L.P., an estimated $77.3M position sold in full.
By sector, the portfolio is most concentrated in Energy at 83% of assets, up from 68% a quarter earlier, followed by Healthcare and Utilities.
Against the trend, Virtus ETF Advisers opened a new position in Amyris Inc. worth $251K.
- Virtus ETF Advisers's largest Q4 2018 buy was Amyris Inc.: 75,294 shares worth $251K.
- Virtus ETF Advisers added most to Energy Transfer Partners in Q4 2018, an estimated $50.2M increase.
- Virtus ETF Advisers's biggest Q4 2018 reduction was Marathon Petroleum, cutting an estimated $28.8M.
- Virtus ETF Advisers fully exited Energy Transfer Partners, L.P. in Q4 2018, selling an estimated $77.3M.
- Virtus ETF Advisers's ten largest holdings make up 61% of its $585M portfolio in Q4 2018.
- Virtus ETF Advisers opened 88 new positions and closed 122 in Q4 2018.
- Virtus ETF Advisers's portfolio value fell 40% quarter-over-quarter to $585M.
Based on Virtus ETF Advisers's 13F filing for Q4 2018, filed 5 Feb 2019.